Markets & Finance

S&P Adds Martek to Its Top 10 List


On May 13, Standard & Poor's equity research group made changes to the S&P Top 10 portfolio -- those issues it considers to be the best candidates for capital gains over the next 6 to 12 months. Martek Biosciences (MATK), a maker of nutritional supplements and food ingredients, has been tapped to replace auto-products chain AutoZone (AZO).

AutoZone was removed from the portfolio after it was downgraded to 3 STARS (hold) from 5 STARS (strong buy) on May 13. S&P analyst Efraim Levy lowered the ranking on the shares, as the retailer reached S&P's price target. S&P's proprietary

discounted cash flow (DCF) model suggested an intrinsic value of $89 per share. While the shares could appreciate further, notes Levy, S&P considers the risk/reward balance less favorable.

S&P believes Martek has the potential to more than double revenues in fiscal 2003 (ending October), driven by increased market demand for infant formula containing its patented additive (see BW Online, 4/21/03, "Martek's Growth Factor "). Analyst Markos Kaminis sees operating earnings per share of 50 cents in fiscal 2003 and $1.31 in fiscal 2004. Based on free cash flow assumptions embedded in our DCF model, we calculate an intrinsic valuation for Martek of $41, which is also our 12-month price target for the shares.

Martek is ranked strong buy by S&P, along with the other names in the portfolio. Year-to-date through Apr. 30, the S&P Top Ten Portfolio gained 3.98%, slightly behind the 4.22% advance for its benchmark, the S&P 500-stock index.

Here's the latest list:

S&P Top 10 Portfolio

Company

Current Price

(5/13/03 close)

12-Month Target

Investment Rationale

Alberto-Culver (ACV)

50.17

59

Attractive on a valuation basis

Boston Scientific (BSX)

48.10

62

Explosive growth prospects

Comcast (CMCSA)

30.31

33

Foreign exchange trends, recent share-price drop

Compass Bancshares (CBSS)

34.84

37

Valuation, positive fundamental trends

Dean Foods (DF)

44.45

47

New products, improved distribution

Jacobs Engineering (JEC)

42.15

48

See strong bookings from refining customers

Martek Biosciences(MATK)

33.31

41

Annual revenue growth of nearly 100% seen through fiscal 2004

Nabors Industries (NBR)

41.96

51

Natural-gas activity expected to rise

Pfizer (PFE)

33.29

38

Trading at a discount to its industry peers

USA Interactive (USAI)

35.25

44

Rising Internet use and usage

For more information about the Top 10 portfolio, please visit http://www.businessweek.com/investor/content/jun2002/pi20020617_8998.htm By Ken Shea and Robert Gold


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus